IMMUNEONCO-B: Application for Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma
I'm PortAI, I can summarize articles.
IMMUNEONCO-B has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of China. IMM0306 is a bispecific molecule targeting CD47 and CD20, the first of its kind to enter clinical stages globally. The drug enhances the activity of macrophages and NK cells by inhibiting the CD47-SIRPα interaction, effectively eliminating malignant B cells, reducing toxicity, and improving therapeutic efficacy. The company holds global intellectual property and commercialization rights for IMM0306
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments